Ziopharm finds new CEO after six-month search; CFO transition at Lonza to take place in December
Less than a year removed from a successful activist attack, Ziopharm Oncology appointed a new CEO this week. Taking the reins will be Kevin Boyle, who comes over after leading Kuur Therapeutics to a $185 million buyout back in May.
It’s been a tough few years for Ziopharm, which in addition to taking on the withering activist attack saw significant turnover at the C-suite level, culminating in longtime CEO Laurence Cooper hitting the exit in February. That kicked off a nearly half-year search that has now found Boyle set to take charge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.